(Q44623883)

English

Subcutaneous interleukin‐2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters

scientific article published on July 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Subcutaneous interleukin‐2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters (English)

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

medroxyprogesterone acetate

1 reference

based on heuristic

inferred from title

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

2

object named as

Clelia Madeddu

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14567291

22 March 2024

author name string

Giovanni Mantovani

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Giulia Gramignano

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Maria Rita Lusso

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Miria Mocci

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Elena Massa

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Luca Ferreli

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Giorgio Astara

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Antonio Macciò

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Roberto Serpe

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1359-4117.2003.01096.x

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1359-4117.2003.01096.x

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Journal of Experimental Therapeutics & Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

205-219

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Oxidative stress: oxidants and antioxidants

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

alpha-Lipoic acid as a biological antioxidant

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586)

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01096.X

21 January 2018

Interleukin-2: inception, impact, and implications

4

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

The interleukin-2 T-cell system: a new cell growth model.

5

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features

7

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

9

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study

10

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy.

11

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Uncomplicated starvation versus cancer cachexia

15

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Design of clinical trials with biological response modifiers

23

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression

31

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment

32

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Reporting results of cancer treatment

35

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU

39

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils

42

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Prognostic significance of peripheral lymphocyte counts and carcinoembryonic antigens in colorectal carcinoma

43

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Analysis of survival by tumor response.

48

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

49

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer

53

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneo

56

1 reference

10.1046/J.1359-4117.2003.01096.X

https://api.crossref.org/works/10.1046/J.1359-4117.2003.01096.X

22 March 2024

Identifiers

10.1046/J.1359-4117.2003.01096.X

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44623883&oldid=2110144409"